首页 > 最新文献

Journal of Medical Imaging and Radiation Oncology最新文献

英文 中文
Abstract 摘要
IF 1.4 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-10-01 DOI: 10.1111/1754-9485.70006
{"title":"Abstract","authors":"","doi":"10.1111/1754-9485.70006","DOIUrl":"https://doi.org/10.1111/1754-9485.70006","url":null,"abstract":"","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"69 S1","pages":"S18-S21"},"PeriodicalIF":1.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1754-9485.70006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145196317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 摘要
IF 1.4 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-10-01 DOI: 10.1111/1754-9485.70005
{"title":"Abstract","authors":"","doi":"10.1111/1754-9485.70005","DOIUrl":"https://doi.org/10.1111/1754-9485.70005","url":null,"abstract":"","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"69 S1","pages":"S4-S6"},"PeriodicalIF":1.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1754-9485.70005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145196310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 摘要
IF 1.4 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-10-01 DOI: 10.1111/1754-9485.70008
{"title":"Abstract","authors":"","doi":"10.1111/1754-9485.70008","DOIUrl":"https://doi.org/10.1111/1754-9485.70008","url":null,"abstract":"","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"69 S1","pages":"S7-S11"},"PeriodicalIF":1.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1754-9485.70008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145196311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 摘要
IF 1.4 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-10-01 DOI: 10.1111/1754-9485.70007
{"title":"Abstract","authors":"","doi":"10.1111/1754-9485.70007","DOIUrl":"https://doi.org/10.1111/1754-9485.70007","url":null,"abstract":"","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"69 S1","pages":"S12-S17"},"PeriodicalIF":1.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1754-9485.70007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145196312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Allan O. Langlands: A Giant of Radiation Oncology in Australia Allan O. Langlands:澳大利亚放射肿瘤学的巨人
IF 1.4 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-09-30 DOI: 10.1111/1754-9485.70027
J. Boyages, A. Rodger, K. W. Tiver, V. Ahern
<p>Allan Ogilvie Langlands AM (1931–2025) was a pioneer, mentor, and one of the most influential figures in Australian radiation oncology. His passing on 28 March 2025 marks the end of an era, but his legacy continues through the generations of clinicians he trained and the countless patients whose lives were touched by his vision.</p><p>Born in Scotland in 1931, Langlands demonstrated early academic brilliance, graduating BSc (Hons) in Physiology in 1953 and MB ChB with Honours from the University of Edinburgh in 1956, where he was awarded the Gold Medal. At that time, the award of Honours MB ChB in Edinburgh—based on performance across the entire course—was rare and often unique in Edinburgh Medical School well into the 1980s, with few, if any, recipients in a given year. Following national service with the Royal Army Medical Corps, he trained in radiotherapy in Edinburgh, joining the MRC Clinical Effects of Radiation Research Unit at the Western General Hospital. His early research focused on leukaemogenesis, thorium exposure, and biological dosimetry—critical topics in a field just beginning to understand radiation's long-term biological impacts.</p><p>From 1969 to 1978, Langlands was Consultant Radiation Oncologist at the Western General and Edinburgh Royal Infirmary, engaging in major UK breast cancer trials. In Edinburgh, he made a lasting impact on breast cancer care across Scotland. At that time, and before his move to Australia, simple mastectomy and radiotherapy—the ‘McWhirter technique’ inherited from Prof Robert McWhirter—were the standard, and Allan did not seek to change this within the 1970s context. He credited much of his early clinical grounding to Professor Robert McWhirter—a giant of British radiotherapy—who instilled in him a scientific rigour and curiosity that shaped the rest of his career.</p><p>In 1978, Langlands accepted the challenge of building a radiation oncology department from the ground up at the new Westmead Hospital in Sydney. It was a pivotal moment for oncology in Australasia. As the first Clinical Professor of Radiation Oncology in the region, he established a comprehensive clinical service and a research and training hub that became a model for other departments. By the time he retired in 1997, Westmead's department housed multiple linear accelerators, brachytherapy services, and more than 70 staff.</p><p>Langlands' clinical passion remained breast cancer, a field in which he made profound international contributions. He led early efforts advocating for breast conservation over mastectomy, emphasising the importance of systemic therapies alongside radiation. He spearheaded multidisciplinary clinics in breast, gynaecological, oesophageal, and haematological malignancies. In Edinburgh, he worked alongside, and often stood up to, influential and powerful surgeons, as there were no trained medical oncologists at the time—only a few physicians dabbling in chemotherapy without formal training and expertise. Despi
Allan Ogilvie Langlands AM(1931-2025)是澳大利亚放射肿瘤学领域的先驱、导师和最有影响力的人物之一。他于2025年3月28日逝世,标志着一个时代的结束,但他的遗产将通过他培养的几代临床医生和无数因他的远见而感动的患者传承下去。朗兰兹1931年出生于苏格兰,早年在学术上表现出色,1953年获得生理学(荣誉)学士学位,1956年获得爱丁堡大学荣誉学士学位,并被授予金质奖章。在那个时候,爱丁堡医学院的荣誉学士学位是基于整个课程的表现而颁发的,这在进入20世纪80年代的爱丁堡医学院是罕见的,而且往往是独一无二的,即使有,在某一年也很少有获得者。在皇家陆军医疗队服役后,他在爱丁堡接受放射治疗培训,加入了西部综合医院MRC放射临床效果研究小组。他早期的研究集中在白血病的发生、钍的暴露和生物剂量学——这是一个刚刚开始了解辐射的长期生物影响的领域的关键主题。从1969年到1978年,Langlands是西部总医院和爱丁堡皇家医院的放射肿瘤学顾问,参与了英国主要的乳腺癌试验。在爱丁堡,他对整个苏格兰的乳腺癌治疗产生了持久的影响。当时,在他搬到澳大利亚之前,简单的乳房切除术和放射治疗——从罗伯特·麦克沃特教授那里继承的“麦克沃特技术”——是标准的,艾伦在20世纪70年代并没有试图改变这一点。他早期的临床基础很大程度上归功于罗伯特·麦克沃特教授——一位英国放射治疗的巨人——他向他灌输了科学的严谨性和好奇心,这影响了他后来的职业生涯。1978年,朗兰兹接受了在悉尼新韦斯特米德医院(Westmead Hospital)从零开始建立一个放射肿瘤科的挑战。这是大洋洲肿瘤学的关键时刻。作为该地区第一位放射肿瘤学临床教授,他建立了全面的临床服务和研究培训中心,成为其他部门的典范。到他1997年退休时,韦斯特米德所在的部门已经拥有多个线性加速器、近距离治疗服务和70多名员工。朗兰兹的临床热情仍然是乳腺癌,他在这个领域做出了深远的国际贡献。他领导了早期倡导乳房保护而不是乳房切除术的努力,强调全身治疗和放疗的重要性。他领导了乳腺、妇科、食道和血液恶性肿瘤的多学科诊所。在爱丁堡,他和有影响力的外科医生一起工作,而且经常与他们对抗,因为当时没有受过训练的肿瘤内科医生——只有少数医生在没有正式培训和专业知识的情况下涉猎化疗。尽管偶尔会发生冲突,但他成功地与外科同事合作进行了早期的随机对照试验,并建立了乳腺癌和肉瘤的多学科诊所。他还亲自建立了一个综合数据库,记录了自20世纪50年代以来在爱丁堡接受治疗的所有乳腺癌患者,并与统计学家吉莉安·克尔(Gillian Kerr)一起进行了细致的随访。这一资源在他移民后得到了很好的更新,为一些重要的出版物做出了贡献,这些出版物表明,在辅助治疗前的时代,乳腺癌在首次治疗后几十年仍然无法治愈。这些合作模式成为了澳大利亚综合护理路径的基础。他发表了160多篇同行评议的文章。他的研究影响了分期、局部控制策略和系统治疗整合,始终以患者为中心。他也是早期倡导更好的结果跟踪、生活质量测量和护理成本效益的人。朗兰兹的国家领导能力令人敬畏。作为当时澳大拉西亚皇家放射学院(RACR)的首席审查员,他帮助制定了下一代放射肿瘤学家的培训课程和考试标准。他是NHMRC 1995年早期乳腺癌国家指南的主要贡献者,并为澳大利亚几个州的癌症服务规划提供咨询。他参与了澳大利亚电离辐射咨询委员会、新南威尔士州癌症委员会和国家乳房研究委员会,帮助确保放射肿瘤学在政策桌上占有一席之地。他强烈主张向医科学生讲授放射肿瘤学。他还在国际环境中提供咨询,包括在巴布亚新几内亚,他支持当地癌症服务的发展。他退休后的日子也同样活跃,在英国国家健康与医学研究委员会临床试验中心担任荣誉职位,并在肿瘤学领域担任医学法律顾问。 在众多荣誉中,他于1996年获得RANZCR金奖,并于2000年获得新南威尔士州癌症委员会专业卓越奖。1997年,他被授予澳大利亚勋章(AM),以表彰他对医学,特别是乳腺癌的贡献。朗兰兹真正的杰出之处在于他将科学的精确性与深刻的人性相结合的能力。他是一位真正意义上的导师——支持我、要求我、鼓舞我。他有一种天赋,可以释放学员的潜力,经常把他们推到舒适区之外。如果他没有得到他想要的答案,他会说:“到目前为止,没有得分”,以鼓励他对眼前的问题进行更深入的思考。他以用冰淇淋打赌来挑战晚辈的临床决策而闻名——这种赌注他很少输。在爱丁堡,他以同样的方式激励和支持实习生、物理学家和其他人,尽管没有冰淇淋赌注,他在离开后很长一段时间里仍被那些专业团体中的许多人怀念和深情地记住。当某件事做得很好时,他会轻描淡写地称赞:“你可以再待一个星期。”如果你犹豫了,你马上就知道了。他周一早上给注册员上的课是传奇般的;如果你迟到了,你肯定知道这件事。他的导师风格既培养了韧性,也培养了知识。他的许多学员后来成为澳大利亚、新西兰和国外主要部门的领导。他培养了一种卓越、正直和循证实践的文化。他还鼓励谦逊和幽默,经常用他的机智化解压力。在2006年的《乳房》回顾中,他回顾了放射治疗从钴机到适形技术的转变,并超越了[1]。他对未来的进步表示乐观,但警告不要自满、技术过度使用和商业影响。退休后,他继续写作,他的作品仍然是实习生和临床医生的必读读物。朗兰兹的工作超越了诊所和演讲厅。他与卫生经济学家、流行病学家和消费者权益倡导者密切合作,为有关医疗保健价值、资源分配和幸存者的全国性讨论做出了贡献。几十年来,他的广阔视野帮助塑造了澳大利亚的癌症控制议程。据他的家人说,他支持米德洛锡安之心足球俱乐部,小时候和父亲一起观看泰纳卡斯尔的比赛,并在他的一生中继续关注他们的进步。他也喜欢关注英超联赛。此外,他对橄榄球联盟有着毕生的热情,尤其是在苏格兰,并且会在访问期间参加在默里菲尔德举行的国际比赛——人们怀疑他是否选择了同样的日期。朗兰兹身后留下了他的孩子吉莉安(Gillian)和科林(Colin),以及孙子帕特里夏(Patricia)和柯克(Kirk)。他深爱的妻子海伦于2018年去世。20世纪50年代中期,他在RAMC服役期间,被派往新加坡的英国军事医院,两人相识,这种伙伴关系持续了几十年。他在澳大利亚和苏格兰的同事和前学员都记得他是放射肿瘤学领域的杰出人物。尽管他在澳大利亚的职业生涯长达数十年,巩固了他作为该领域领导者的地位,但朗兰兹在苏格兰也留下了持久的遗产,尽管时间较短。在那里,他为自己的临床方法奠定了基础,指导了未来的领导者,开发了服务,并影响了癌症治疗。他的性格——有时易怒,经常对抗,但总是有原则——与他的成就密不可分,并且仍然是世界两岸同事对他的记忆的核心。在他的葬礼上,他的女儿反映说,他之所以决定移民到澳大利亚,是因为在麦克沃特教授退休后,他没有被任命为爱丁堡放射治疗中心的主席,这在当时的爱丁堡被广泛认为是一个结果。对这个家族来说,这是一个重大的剧变,但苏格兰的损失变成了澳大利亚和新西兰的收获。他的影响已经融入了这个国家放射肿瘤学的DNA中。Boyages:构思,写作-原稿。罗杰:写作-评论和编辑。K. W.蒂弗:写作——原稿。V.埃亨:构思,写作-原稿。作者声明无利益冲突。数据共享不适用于本文,因为在当前研究期间没有生成或分析数据集。
{"title":"Allan O. Langlands: A Giant of Radiation Oncology in Australia","authors":"J. Boyages,&nbsp;A. Rodger,&nbsp;K. W. Tiver,&nbsp;V. Ahern","doi":"10.1111/1754-9485.70027","DOIUrl":"https://doi.org/10.1111/1754-9485.70027","url":null,"abstract":"&lt;p&gt;Allan Ogilvie Langlands AM (1931–2025) was a pioneer, mentor, and one of the most influential figures in Australian radiation oncology. His passing on 28 March 2025 marks the end of an era, but his legacy continues through the generations of clinicians he trained and the countless patients whose lives were touched by his vision.&lt;/p&gt;&lt;p&gt;Born in Scotland in 1931, Langlands demonstrated early academic brilliance, graduating BSc (Hons) in Physiology in 1953 and MB ChB with Honours from the University of Edinburgh in 1956, where he was awarded the Gold Medal. At that time, the award of Honours MB ChB in Edinburgh—based on performance across the entire course—was rare and often unique in Edinburgh Medical School well into the 1980s, with few, if any, recipients in a given year. Following national service with the Royal Army Medical Corps, he trained in radiotherapy in Edinburgh, joining the MRC Clinical Effects of Radiation Research Unit at the Western General Hospital. His early research focused on leukaemogenesis, thorium exposure, and biological dosimetry—critical topics in a field just beginning to understand radiation's long-term biological impacts.&lt;/p&gt;&lt;p&gt;From 1969 to 1978, Langlands was Consultant Radiation Oncologist at the Western General and Edinburgh Royal Infirmary, engaging in major UK breast cancer trials. In Edinburgh, he made a lasting impact on breast cancer care across Scotland. At that time, and before his move to Australia, simple mastectomy and radiotherapy—the ‘McWhirter technique’ inherited from Prof Robert McWhirter—were the standard, and Allan did not seek to change this within the 1970s context. He credited much of his early clinical grounding to Professor Robert McWhirter—a giant of British radiotherapy—who instilled in him a scientific rigour and curiosity that shaped the rest of his career.&lt;/p&gt;&lt;p&gt;In 1978, Langlands accepted the challenge of building a radiation oncology department from the ground up at the new Westmead Hospital in Sydney. It was a pivotal moment for oncology in Australasia. As the first Clinical Professor of Radiation Oncology in the region, he established a comprehensive clinical service and a research and training hub that became a model for other departments. By the time he retired in 1997, Westmead's department housed multiple linear accelerators, brachytherapy services, and more than 70 staff.&lt;/p&gt;&lt;p&gt;Langlands' clinical passion remained breast cancer, a field in which he made profound international contributions. He led early efforts advocating for breast conservation over mastectomy, emphasising the importance of systemic therapies alongside radiation. He spearheaded multidisciplinary clinics in breast, gynaecological, oesophageal, and haematological malignancies. In Edinburgh, he worked alongside, and often stood up to, influential and powerful surgeons, as there were no trained medical oncologists at the time—only a few physicians dabbling in chemotherapy without formal training and expertise. Despi","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"69 8","pages":"787-789"},"PeriodicalIF":1.4,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1754-9485.70027","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145659708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Formal Outpatient Clinics in Interventional Radiology: An Essential Component of Modern Practice 介入放射学的正式门诊诊所:现代实践的重要组成部分。
IF 1.4 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-09-29 DOI: 10.1111/1754-9485.70028
Asare Augustine Amoafo, Diederick Willem De Boo, Matthew William Lukies

Interventional Radiology (IR) is a relatively young specialty that has experienced rapid development since Charles Dotter performed the first percutaneous transluminal angioplasty in 1964. Since then, IR has expanded to include a diverse array of minimally invasive image-guided procedures. It was the same Charles Dotter who early on recognized that the Interventional Radiologist must be involved in patient care as a true clinician, not just a skilled mechanic. However, outpatient and periprocedural clinical patient management by IR has remained underdeveloped when compared to the significant procedural advancements seen over the past four decades. We present local Australian health service data reinforcing the value of formal outpatient clinics in delivering adequate patient counselling, improving consent rates prior to the procedure day, and decreasing costly day-of-procedure cancellations and reschedulling.

介入放射学(IR)是一个相对年轻的专业,自1964年Charles Dotter首次进行经皮腔内血管成形术以来经历了快速发展。从那时起,红外已经扩展到包括各种微创图像引导程序。同样是查尔斯·波特,他很早就认识到介入放射科医生必须作为一个真正的临床医生参与病人的护理,而不仅仅是一个熟练的机械师。然而,与过去40年的重大进展相比,门诊和围手术期临床患者管理仍然不发达。我们提供了澳大利亚当地的卫生服务数据,加强了正规门诊诊所在提供充分的患者咨询、提高手术前的同意率和减少昂贵的手术当日取消和重新安排方面的价值。
{"title":"Formal Outpatient Clinics in Interventional Radiology: An Essential Component of Modern Practice","authors":"Asare Augustine Amoafo,&nbsp;Diederick Willem De Boo,&nbsp;Matthew William Lukies","doi":"10.1111/1754-9485.70028","DOIUrl":"10.1111/1754-9485.70028","url":null,"abstract":"<p>Interventional Radiology (IR) is a relatively young specialty that has experienced rapid development since Charles Dotter performed the first percutaneous transluminal angioplasty in 1964. Since then, IR has expanded to include a diverse array of minimally invasive image-guided procedures. It was the same Charles Dotter who early on recognized that the Interventional Radiologist must be involved in patient care as a true clinician, not just a skilled mechanic. However, outpatient and periprocedural clinical patient management by IR has remained underdeveloped when compared to the significant procedural advancements seen over the past four decades. We present local Australian health service data reinforcing the value of formal outpatient clinics in delivering adequate patient counselling, improving consent rates prior to the procedure day, and decreasing costly day-of-procedure cancellations and reschedulling.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"69 8","pages":"825-828"},"PeriodicalIF":1.4,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1754-9485.70028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gender-Based Outcomes in Grants, Prizes and Fellowship Success Rates in Clinical Radiology: A 14-Year Review of Outcomes in Australia and New Zealand 基于性别的临床放射学资助、奖励和奖学金成功率:澳大利亚和新西兰14年研究结果综述
IF 1.4 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-09-24 DOI: 10.1111/1754-9485.70019
Jack Edward Liu, Lisa Milner, Behnam Shaygi, Michael Stewart, Anousha Yazdabadi, Julian Maingard, Hong Kuan Kok, Numan Kutaiba, Christen D. Barras, Paul Maria Parizel, Hamed Asadi

Introduction

While gender disparities in the radiology workforce are well-documented, there has been no analysis of outcomes for competitive awards in Australia and New Zealand. As formal recognition is critical for career progression, this study aimed to investigate gender-based differences in application and success rates for grants, prizes and educational fellowships within the Australasian context.

Methods

We retrospectively reviewed applications for Royal Australian and New Zealand College of Radiologists' (RANZCR) Faculty of Clinical Radiology grants, prizes and educational fellowships from 2011 to 2024. Application and success rates were stratified by gender and compared to College membership demographics. Significance was assessed using Fisher's exact test.

Results

Across 333 total applications, 227 (68.2%) were from males and 106 (31.8%) from females, closely reflecting College membership gender ratios (69.2% male vs. 30.8% female). No significant gender disparity was found in the success rates for grants (40.3% for males vs. 35.0% for females, p = 0.58), prizes (8.8% vs. 11.1%, p = 0.08) or educational fellowships (36.7% vs. 32.1%, p = 0.32). Application rates for each award type also broadly reflected the gender composition of the College membership.

Conclusion

This study is the first to examine gender differences in clinical radiology grant, prize and educational fellowship outcomes in Australia and New Zealand. We found no significant disparities in success rates, and application rates generally mirrored College membership, suggesting the award process itself is equitable. However, the continued underrepresentation of women in radiology underscores the need to examine broader structural and sociocultural factors that may impact engagement with competitive academic opportunities.

导言:虽然在放射科工作人员中的性别差异有充分的记录,但在澳大利亚和新西兰,没有对竞争性奖项的结果进行分析。由于正式认可对职业发展至关重要,本研究旨在调查在澳大利亚范围内补助金、奖金和教育奖学金的申请和成功率方面的性别差异。方法:我们回顾性地回顾了2011年至2024年澳大利亚和新西兰皇家放射科医师学院(RANZCR)临床放射学资助、奖励和教育奖学金的申请。申请和成功率按性别分层,并与大学会员人口统计数据进行比较。采用Fisher精确检验评估显著性。结果:在333份申请中,227份(68.2%)来自男性,106份(31.8%)来自女性,密切反映了学院成员的性别比例(69.2%男性对30.8%女性)。在助学金(男性为40.3%,女性为35.0%,p = 0.58)、奖金(8.8%,女性为11.1%,p = 0.08)或教育奖学金(36.7%,女性为32.1%,p = 0.32)的成功率方面,没有发现显著的性别差异。每种奖项的申请比例也广泛反映了学院成员的性别构成。结论:本研究首次对澳大利亚和新西兰临床放射学资助、奖励和教育奖学金结果的性别差异进行了研究。我们发现在成功率上没有明显的差异,而且申请率基本上反映了学院成员资格,这表明奖励过程本身是公平的。然而,女性在放射学领域的持续代表性不足强调了研究更广泛的结构和社会文化因素的必要性,这些因素可能会影响她们参与竞争性的学术机会。
{"title":"Gender-Based Outcomes in Grants, Prizes and Fellowship Success Rates in Clinical Radiology: A 14-Year Review of Outcomes in Australia and New Zealand","authors":"Jack Edward Liu,&nbsp;Lisa Milner,&nbsp;Behnam Shaygi,&nbsp;Michael Stewart,&nbsp;Anousha Yazdabadi,&nbsp;Julian Maingard,&nbsp;Hong Kuan Kok,&nbsp;Numan Kutaiba,&nbsp;Christen D. Barras,&nbsp;Paul Maria Parizel,&nbsp;Hamed Asadi","doi":"10.1111/1754-9485.70019","DOIUrl":"10.1111/1754-9485.70019","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>While gender disparities in the radiology workforce are well-documented, there has been no analysis of outcomes for competitive awards in Australia and New Zealand. As formal recognition is critical for career progression, this study aimed to investigate gender-based differences in application and success rates for grants, prizes and educational fellowships within the Australasian context.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively reviewed applications for Royal Australian and New Zealand College of Radiologists' (RANZCR) Faculty of Clinical Radiology grants, prizes and educational fellowships from 2011 to 2024. Application and success rates were stratified by gender and compared to College membership demographics. Significance was assessed using Fisher's exact test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Across 333 total applications, 227 (68.2%) were from males and 106 (31.8%) from females, closely reflecting College membership gender ratios (69.2% male vs. 30.8% female). No significant gender disparity was found in the success rates for grants (40.3% for males vs. 35.0% for females, <i>p</i> = 0.58), prizes (8.8% vs. 11.1%, <i>p</i> = 0.08) or educational fellowships (36.7% vs. 32.1%, <i>p</i> = 0.32). Application rates for each award type also broadly reflected the gender composition of the College membership.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study is the first to examine gender differences in clinical radiology grant, prize and educational fellowship outcomes in Australia and New Zealand. We found no significant disparities in success rates, and application rates generally mirrored College membership, suggesting the award process itself is equitable. However, the continued underrepresentation of women in radiology underscores the need to examine broader structural and sociocultural factors that may impact engagement with competitive academic opportunities.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"69 8","pages":"798-803"},"PeriodicalIF":1.4,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elderly Patients With Glioblastoma and Good Prognostic Factors May Achieve Equivalent Median Survival to Younger Patients When Managed With Standard Long-Course Rather Than Elderly Protocols 老年胶质母细胞瘤患者预后良好,如果采用标准的长期治疗方案而不是老年治疗方案,其中位生存期可能与年轻患者相当。
IF 1.4 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-09-19 DOI: 10.1111/1754-9485.70020
Anneka Parker, Patrick Horsley, Helen Wheeler, Venkatesha Venkatesha, Marina Kastelan, Brendan Liu, Michael Back

Introduction

Decision-making for adjuvant therapy regimen of elderly patients with glioblastoma may be based on age alone rather than prognostic factors. This study assesses treatment outcomes for elderly patients with good prognostic factors managed with the EORTC-NCIC Protocol.

Methods

Patients treated for glioblastoma with adjuvant chemoradiotherapy in accordance with the EORTC-NCIC (Stupp) Protocol between 2008 and 2021 were entered into a prospective database. Outcomes for patients aged < 65 were compared to those ≥ 65 years, divided into subgroups 65–70, 70–74 and > 75 years. Overall survival (OS) and progression-free survival (PFS) were the primary and secondary endpoints, respectively.

Results

The study included 437 patients, of whom 319 were aged < 65 and 118 were aged ≥ 65 years. Median OS was 19.2 months for patients aged < 65 years and 15.0 months for those aged ≥ 65 years (p = 0.006). Median PFS were 12.0 and 11.3 months, respectively (p = 0.119). For both age groups, performance status, extent of resection and MGMT methylation were significant predictors of overall survival. Age group was not a significant predictor of OS when these factors were accounted for (p = 0.237).

Conclusion

When stratified for performance status and MGMT methylation, elderly patients had similar outcomes compared with the younger cohort. This suggests that elderly patients who managed well following diagnosis and subsequent surgical procedure may be optimally treated with long-course standard rather than elderly protocols.

老年胶质母细胞瘤患者辅助治疗方案的决策可能仅基于年龄而非预后因素。本研究评估了采用EORTC-NCIC方案管理预后因素良好的老年患者的治疗结果。方法:将2008年至2021年间按照EORTC-NCIC (Stupp)协议接受辅助放化疗的胶质母细胞瘤患者纳入前瞻性数据库。75岁患者的结局。总生存期(OS)和无进展生存期(PFS)分别是主要和次要终点。结果:该研究纳入了437例患者,其中319例为老年患者。结论:当对表现状态和MGMT甲基化进行分层时,老年患者与年轻患者的结果相似。这表明,在诊断和随后的外科手术后处理良好的老年患者可能优选长期标准治疗方案,而不是老年方案。
{"title":"Elderly Patients With Glioblastoma and Good Prognostic Factors May Achieve Equivalent Median Survival to Younger Patients When Managed With Standard Long-Course Rather Than Elderly Protocols","authors":"Anneka Parker,&nbsp;Patrick Horsley,&nbsp;Helen Wheeler,&nbsp;Venkatesha Venkatesha,&nbsp;Marina Kastelan,&nbsp;Brendan Liu,&nbsp;Michael Back","doi":"10.1111/1754-9485.70020","DOIUrl":"10.1111/1754-9485.70020","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Decision-making for adjuvant therapy regimen of elderly patients with glioblastoma may be based on age alone rather than prognostic factors. This study assesses treatment outcomes for elderly patients with good prognostic factors managed with the EORTC-NCIC Protocol.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients treated for glioblastoma with adjuvant chemoradiotherapy in accordance with the EORTC-NCIC (Stupp) Protocol between 2008 and 2021 were entered into a prospective database. Outcomes for patients aged &lt; 65 were compared to those ≥ 65 years, divided into subgroups 65–70, 70–74 and &gt; 75 years. Overall survival (OS) and progression-free survival (PFS) were the primary and secondary endpoints, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study included 437 patients, of whom 319 were aged &lt; 65 and 118 were aged ≥ 65 years. Median OS was 19.2 months for patients aged &lt; 65 years and 15.0 months for those aged ≥ 65 years (<i>p</i> = 0.006). Median PFS were 12.0 and 11.3 months, respectively (<i>p</i> = 0.119). For both age groups, performance status, extent of resection and MGMT methylation were significant predictors of overall survival. Age group was not a significant predictor of OS when these factors were accounted for (<i>p</i> = 0.237).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>When stratified for performance status and MGMT methylation, elderly patients had similar outcomes compared with the younger cohort. This suggests that elderly patients who managed well following diagnosis and subsequent surgical procedure may be optimally treated with long-course standard rather than elderly protocols.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"69 8","pages":"844-851"},"PeriodicalIF":1.4,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145086195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating New Frontiers: Initial Auckland Experience of Seed Localisation Techniques for Breast Conserving Surgery 导航新领域:保乳手术种子定位技术的奥克兰初步经验。
IF 1.4 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-09-18 DOI: 10.1111/1754-9485.70024
Yousr Al-Sheibani, Andrew MacDonald, Kaye Wang

Introduction

Breast conserving surgery for non-palpable tumours requires imaging-guided localisation, historically achieved with hookwire localisation (HWL). HWL, however, has recognised shortcomings including the need for same-day surgery with associated radiology resource/logistical constraints, psychological impact of wire protrusion, and complications such as wire displacement or fracture. The introduction of novel non-wire surgical marker navigation (SMN) techniques offers promising benefits. This study evaluates the early implementation of SMN (Sirius Pintuition and Merit SAVISCOUT systems) in one radiology department in Auckland, New Zealand.

Methods

This is a retrospective cohort study evaluating surgical outcomes in patients with non-palpable tumours who underwent preoperative localisation between May 2023 and June 2024. Three groups were compared: two cohorts who underwent SMN in the form of Pintution (n = 36) and SAVISCOUT (n = 42) and one who underwent HWL (n = 35). Surgical outcomes assessed included histological margin status and rates of re-excision. Technical challenges and complications were recorded.

Results

There was no significant difference in surgical outcomes between HWL and SMN groups. The ‘surgery complete’ rate was 89% in the HWL group, 82% in the Pintuition group, and 97% in the SAVISCOUT group (p = 0.10). Technique failure occurred in five cases of SMN (6%) due to inadequate seed position and one case of HWL (3%) due to wire displacement.

Conclusion

SMN in the form of Pintuition and SAVISCOUT demonstrate comparable surgical outcomes to HWL, whilst also offering advantages in scheduling flexibility and resource utilisation. A small rate of technical failure highlights the operator learning curve and need for appropriate training.

简介:保乳手术对不可触及的肿瘤需要成像引导定位,历史上通过钩线定位(HWL)实现。然而,HWL已经认识到其缺点,包括需要当天手术,相关放射学资源/后勤限制,钢丝突出的心理影响,以及钢丝移位或骨折等并发症。引入新的无丝手术标记导航(SMN)技术提供了有希望的好处。本研究评估了SMN (Sirius Pintuition和Merit SAVISCOUT系统)在新西兰奥克兰的一个放射科的早期实施情况。方法:这是一项回顾性队列研究,评估2023年5月至2024年6月期间接受术前定位的非可触及肿瘤患者的手术结果。对三组进行比较:两组以ptution (n = 36)和SAVISCOUT (n = 42)的形式接受SMN,一组接受HWL (n = 35)。评估手术结果包括组织学边缘状态和再切除率。记录技术挑战和并发症。结果:HWL组与SMN组手术结果无显著差异。HWL组的“手术完成率”为89%,Pintuition组为82%,SAVISCOUT组为97% (p = 0.10)。5例SMN(6%)由于种子位置不合适导致技术失败,1例HWL(3%)由于钢丝移位导致技术失败。结论:Pintuition和SAVISCOUT形式的SMN表现出与HWL相当的手术效果,同时在调度灵活性和资源利用方面也具有优势。小的技术失败率凸显了操作员的学习曲线和对适当培训的需求。
{"title":"Navigating New Frontiers: Initial Auckland Experience of Seed Localisation Techniques for Breast Conserving Surgery","authors":"Yousr Al-Sheibani,&nbsp;Andrew MacDonald,&nbsp;Kaye Wang","doi":"10.1111/1754-9485.70024","DOIUrl":"10.1111/1754-9485.70024","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Breast conserving surgery for non-palpable tumours requires imaging-guided localisation, historically achieved with hookwire localisation (HWL). HWL, however, has recognised shortcomings including the need for same-day surgery with associated radiology resource/logistical constraints, psychological impact of wire protrusion, and complications such as wire displacement or fracture. The introduction of novel non-wire surgical marker navigation (SMN) techniques offers promising benefits. This study evaluates the early implementation of SMN (Sirius Pintuition and Merit SAVISCOUT systems) in one radiology department in Auckland, New Zealand.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This is a retrospective cohort study evaluating surgical outcomes in patients with non-palpable tumours who underwent preoperative localisation between May 2023 and June 2024. Three groups were compared: two cohorts who underwent SMN in the form of Pintution (<i>n</i> = 36) and SAVISCOUT (<i>n</i> = 42) and one who underwent HWL (<i>n</i> = 35). Surgical outcomes assessed included histological margin status and rates of re-excision. Technical challenges and complications were recorded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There was no significant difference in surgical outcomes between HWL and SMN groups. The ‘surgery complete’ rate was 89% in the HWL group, 82% in the Pintuition group, and 97% in the SAVISCOUT group (<i>p</i> = 0.10). Technique failure occurred in five cases of SMN (6%) due to inadequate seed position and one case of HWL (3%) due to wire displacement.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>SMN in the form of Pintuition and SAVISCOUT demonstrate comparable surgical outcomes to HWL, whilst also offering advantages in scheduling flexibility and resource utilisation. A small rate of technical failure highlights the operator learning curve and need for appropriate training.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"69 8","pages":"790-797"},"PeriodicalIF":1.4,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145081000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantifying Interfractional Motion in Patients With Anorectal Cancer During Radiotherapy and Recommendations of Optimal Planning Target Volume Margins 肛肠癌患者放射治疗过程中分数间运动的量化及最佳规划靶体积边界的建议。
IF 1.4 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-09-17 DOI: 10.1111/1754-9485.70022
Ye Jin Yoo, Youngmoon Goh, Hanyong Kim, Jin-hong Park

Introduction

This study aimed to assess pelvic organ motion and volume changes during long-course radiation therapy (LCRT) for anorectal cancer and propose an optimal planning target volume (PTV) margin.

Method

This retrospective study analysed 526 daily cone-beam computed tomography (CBCT) from 22 patients with anorectal cancer undergoing LCRT. Patients followed a bladder-filling protocol by drinking water before treatment. The bladder, rectum and mesorectum were delineated on planning CT and CBCTs. PTV margins were calculated using the van Herk formula, and margins to cover 95% interfractional motion were also evaluated.

Results

Bladder volume exhibited the higher variability (mean ± standard deviations, 271.3 ± 130.5 mL), compared to the mesorectum (111.3 ± 26.2 mL) and rectum (50.6 ± 15.6 mL). Mesorectum motion showed no significant correlation with bladder volume changes but was significantly associated with rectal volume (r = 0.566; p < 0.001 in the superior mesorectum). Anterior mesorectum motion was larger compared to other directions, particularly in the superior region, with systematic and random variations of 4.4 and 3.5 mm. Using the van Herk formula, PTV margins for the anterior mesorectum were 5.8, 4.9, and 3.3 mm for the superior, middle and inferior regions, respectively. Similarly, margins to cover 95% interfractional movement extended up to 6.7 mm in the superior–anterior region.

Conclusion

Bladder volume varied significantly during LCRT, while mesorectum motion was influenced by rectal volume changes. A 5-mm PTV margin was sufficient for the mid to lower mesorectum, with a larger 7-mm margin needed for the superior–anterior mesorectum. Incorporating 95% interfractional motion coverage further refined these margin recommendations.

简介:本研究旨在评估肛门直肠癌长期放射治疗(LCRT)期间盆腔器官运动和体积的变化,并提出最佳规划靶体积(PTV)范围。方法:回顾性分析22例行LCRT的肛肠直肠癌患者526次日常锥形束计算机断层扫描(CBCT)。患者在治疗前通过饮水进行膀胱填充。膀胱、直肠及肠系膜行计划CT及cbct勾画。使用van Herk公式计算PTV边缘,并评估覆盖95%分数间运动的边缘。结果:与直肠系膜(111.3±26.2 mL)和直肠(50.6±15.6 mL)相比,膀胱体积表现出更高的变异性(平均值±标准差,271.3±130.5 mL)。直肠系膜运动与膀胱体积变化无显著相关性,但与直肠体积有显著相关性(r = 0.566; p)结论:LCRT期间膀胱体积变化显著,而直肠系膜运动受直肠体积变化的影响。5毫米的PTV切缘对于中至下直肠系膜已经足够,对于前上直肠系膜则需要更大的7毫米切缘。纳入95%的分数间运动覆盖率进一步完善了这些边际建议。
{"title":"Quantifying Interfractional Motion in Patients With Anorectal Cancer During Radiotherapy and Recommendations of Optimal Planning Target Volume Margins","authors":"Ye Jin Yoo,&nbsp;Youngmoon Goh,&nbsp;Hanyong Kim,&nbsp;Jin-hong Park","doi":"10.1111/1754-9485.70022","DOIUrl":"10.1111/1754-9485.70022","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>This study aimed to assess pelvic organ motion and volume changes during long-course radiation therapy (LCRT) for anorectal cancer and propose an optimal planning target volume (PTV) margin.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>This retrospective study analysed 526 daily cone-beam computed tomography (CBCT) from 22 patients with anorectal cancer undergoing LCRT. Patients followed a bladder-filling protocol by drinking water before treatment. The bladder, rectum and mesorectum were delineated on planning CT and CBCTs. PTV margins were calculated using the van Herk formula, and margins to cover 95% interfractional motion were also evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Bladder volume exhibited the higher variability (mean ± standard deviations, 271.3 ± 130.5 mL), compared to the mesorectum (111.3 ± 26.2 mL) and rectum (50.6 ± 15.6 mL). Mesorectum motion showed no significant correlation with bladder volume changes but was significantly associated with rectal volume (<i>r</i> = 0.566; <i>p</i> &lt; 0.001 in the superior mesorectum). Anterior mesorectum motion was larger compared to other directions, particularly in the superior region, with systematic and random variations of 4.4 and 3.5 mm. Using the van Herk formula, PTV margins for the anterior mesorectum were 5.8, 4.9, and 3.3 mm for the superior, middle and inferior regions, respectively. Similarly, margins to cover 95% interfractional movement extended up to 6.7 mm in the superior–anterior region.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Bladder volume varied significantly during LCRT, while mesorectum motion was influenced by rectal volume changes. A 5-mm PTV margin was sufficient for the mid to lower mesorectum, with a larger 7-mm margin needed for the superior–anterior mesorectum. Incorporating 95% interfractional motion coverage further refined these margin recommendations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"69 7","pages":"707-714"},"PeriodicalIF":1.4,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145075420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Medical Imaging and Radiation Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1